The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
about
Evaluation of high-dose daptomycin for therapy of experimental Staphylococcus aureus foreign body infection.Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensThe safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001Novel agents for the treatment of resistant Gram-positive infections.Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.Daptomycin.New therapies for pneumococcal meningitis.Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus.Daptomycin - a novel antibiotic against Gram-positive pathogens.Oritavancin--an investigational glycopeptide antibiotic.In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.Update on daptomycin: the first approved lipopeptide antibiotic.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infectionDaptomycin: a review 4 years after first approval.Antimicrobial treatment for intra-abdominal infections.Daptomycin: pharmacology and clinical use.Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infectionsDaptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain.In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis.Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.Daptomycin in the treatment of skin, soft-tissue and invasive infections due to Gram-positive bacteria.Evaluation of new broth media for microdilution antibiotic susceptibility testing of Lactobacilli, Pediococci, Lactococci, and Bifidobacteria.In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection.Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.Physical and chemical compatibility of daptomycin with nine medications.Evaluation of in vitro interaction of daptomycin with gentamicin or beta-lactam antibiotics against Staphylococcus aureus and Enterococci by FIC index and timed-kill curves.Preliminary study of a controllable device for subtenon drug infusion in a rabbit model.Enterococcus faecalis and pathogenic streptococci inactivate daptomycin by releasing phospholipids.
P2860
Q33239640-972AB6A0-6A57-4C66-9E86-B591D73D6741Q33788308-823A02B4-6D63-4109-AAE1-B66CA5989381Q34330270-C9A0DAB8-481E-4644-A58C-C4EAE465F022Q34939045-365EAAFD-BB8B-4D68-9509-1807D5AF01B9Q35056042-DB743A3D-BE34-480B-86D0-66FEEBA788D3Q35166213-A43FCF68-A9EA-49E0-8C48-4237AE11F9F2Q35637066-09A6F9E2-9FB3-498B-91F7-375050BA39F0Q35753477-3D4DADF6-C9EA-459E-8183-F5BB0C9F29F2Q35771368-5EB9107A-9C6C-4434-A7D5-C6609AB2B66CQ35925535-BE34FB69-38FD-43BD-B263-AB329706FAEDQ36426011-ADE2EC58-F73A-4A2B-ABE4-616E08CCC160Q36492244-34EEE887-AA10-49C3-ABC5-6550D1E6F393Q36521880-B34E23E4-DBEC-497D-B296-D50AC7CDA474Q36718474-E89C60C1-A559-4657-831A-DAE3A9A92DC8Q36879791-9C8F11C2-591D-46CC-A66C-01D210614F7FQ36972980-F29F1E22-6A88-4054-873D-C838DB73BBFFQ37000729-C03EE324-737B-40CC-ADF5-2A0F6BBF63FDQ37693931-3204223C-6FD4-4437-AE50-F030E2BBBF8DQ38282725-39DCB254-900A-4A72-9E7A-92C64C3B6F71Q38898667-558117F1-70AC-4CE4-BC88-82EDFF60914FQ38990504-173D0B1E-8BB6-451A-A465-57439761CAE8Q39792691-F1F3F448-4FC0-49A4-A935-32266B35A390Q40166184-3CB96C3B-44BE-48F1-9E32-A3049D30E67FQ40189196-FCE87A25-1F6B-4C03-86DE-BBE410DAA5FDQ40718774-2619758D-DDE7-4542-BB78-CCC95430ECB8Q42107088-23AF6ECD-1D6A-4C3E-9D79-6EE5D61A59E7Q43183404-FE9782CD-F39C-4DF2-BE89-E3E60EB7E5EBQ45029806-9A3E51A5-D633-4AC9-9442-D6D7A8431E0CQ46908684-AD5670ED-4429-4562-992E-8EA8C6E64663Q48300017-7ABB27C0-539A-4AC2-B23E-CFC59D270C78Q49887078-F5AE4192-94CF-4186-90C1-0B40816C5160
P2860
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
@en
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
@nl
type
label
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
@en
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
@nl
prefLabel
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
@en
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
@nl
P356
P1476
The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates.
@en
P2093
P304
P356
10.1093/JAC/48.2.219
P407
P577
2001-08-01T00:00:00Z